Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Celle – page 23

724 clinical trials in Celle, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Celle at a glance
724
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

724 trials in Celle

Open in trial search

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:Biohaven Therapeutics Ltd.

Metapneumovirus infection

Not yet recruiting

Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:IVX-121
  • Sponsor:AstraZeneca AB

Epidermolysis bullosa

Not yet recruiting

Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALLO-APZ2-EB
  • Sponsor:Rheacell GmbH & Co. KG

Acute myeloid leukaemia

Not yet recruiting

A Study to Assess Effectiveness of IPN60340 with Drug Combination in Adults with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ipsen Pharma

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Renal disorder

Not yet recruiting

Study of Surovatamig and Human IgG4 Kappa Monoclonal Antibody Against CD3 and CD19 in Adults with Antibody-Mediated Kidney Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
  • Sponsor:AstraZeneca AB

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Medizinische Hochschule Hannover

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of combination therapy with an endothelin receptor antagonist, phosphodiesterase‑5 inhibitor, and sotatercept in newly diagnosed pulmonary arterial hypertension

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Philipps-Universitaet Marburg

Diabetic retinal oedema

Not yet recruiting

Efficacy and safety of intravitreal MK-8748 versus aflibercept in adults with diabetic macular edema

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Merck Sharp & Dohme LLC

Major depression

Not yet recruiting

Efficacy and Safety of AGN-151607-DP in Adults with Major Depressive Disorder: A Randomized, Placebo‑Controlled Phase 2 Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Celle

What the registry says about research in the country

01 Breast Cancer Research

Clinical studies focusing on triple-negative breast cancer and HER2-negative breast cancer, evaluating innovative treatment approaches in both early and advanced stages of the disease.

  • Advanced Treatment Protocols
  • Chemotherapy Combinations
  • Hormone Receptor Studies

Investigations combining immunotherapy with traditional chemotherapy regimens, aiming to improve survival rates and treatment outcomes for breast cancer patients.

02 Immunotherapy Research

Groundbreaking studies exploring the effectiveness of atezolizumab in combination with established chemotherapy protocols for breast cancer treatment.

  • Neoadjuvant Therapy
  • Adjuvant Treatment
  • Event-Free Survival Analysis

Research focusing on measuring survival rates and analyzing treatment response patterns in advanced breast cancer patients.

03 Molecular Patterns Analysis

Comprehensive research investigating spatial and temporal patterns in breast cancer treatment responses, with particular focus on drug efficacy and resistance mechanisms.

  • Treatment Resistance Studies
  • Progression-Free Survival
  • Overall Survival Analysis

Studies examining therapeutic outcomes in hormone receptor-positive breast cancer patients undergoing first-line treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.